诺华重磅基因疗法或本月获批 最新积极数据涵盖更多SMA患者(10)
2019-05-16 未知 admin
监管机构ICER指出,诺华1型SMA基因疗法若定价200万美元,相比市售唯一药物Spinraza更具成本效益丨医麦猛爆料
面对细胞和基因治疗成本与定价问题,制药巨头诺华公开给出解决方案丨医麦猛爆料
FDA受理诺华1型SMA基因疗法的上市申请,或于明年5月获得批准丨医麦猛爆料
诺华豪掷87亿美元收购的Avexis公司,向FDA提交“重磅”基因疗法上市申请丨医麦猛爆料
参考出处:
http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2397127
https://xconomy.com/national/2019/05/02/sma-moment-will-gene-therapy-shift-treatment-costs-of-muscle-disease/2/
https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-1
https://www.novartis.com/sites/www.novartis.com/files/2018-11-05-r-d-day-investor-presentation.pdf
https://endpts.com/new-zolgensma-data-suggests-comparable-efficacy-to-spinraza-analysts/
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。鐑瘝锛